These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loët X, Tebib J, Sibilia J, Taoufik Y, Dougados M, Mariette X. Arthritis Rheum; 2011 Apr; 63(4):933-8. PubMed ID: 21225699 [Abstract] [Full Text] [Related]
4. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM. Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852 [Abstract] [Full Text] [Related]
5. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D, Rozenbaum M, Rosner I. Ann Rheum Dis; 2007 Jun; 66(6):818-20. PubMed ID: 17148544 [Abstract] [Full Text] [Related]
6. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. Caspi D, Anouk M, Golan I, Paran D, Kaufman I, Wigler I, Levartovsky D, Litinsky I, Elkayam O. Arthritis Rheum; 2006 Feb 15; 55(1):53-6. PubMed ID: 16463412 [Abstract] [Full Text] [Related]
7. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S. Rheumatology (Oxford); 2009 Dec 15; 48(12):1557-9. PubMed ID: 19789202 [Abstract] [Full Text] [Related]
9. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Arthritis Rheum; 2006 Aug 15; 54(8):2377-86. PubMed ID: 16869000 [Abstract] [Full Text] [Related]
12. Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry). Glace B, Gottenberg JE, Mariette X, Philippe R, Pereira B, Lequerré T, Berthelot JM, Dougados M, Toussirot E, Pham T, Allanore Y, Loeuille D, Euller-Ziegler L, Soubrier M. Ann Rheum Dis; 2012 Aug 15; 71(8):1429-31. PubMed ID: 22504557 [No Abstract] [Full Text] [Related]
13. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, Wei N, Boyle DL. Ann Rheum Dis; 2008 Mar 15; 67(3):402-8. PubMed ID: 17644541 [Abstract] [Full Text] [Related]
14. IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis. van Tuyl LH, Lems WF, Kerstens PJ, Voskuyl AE, Dijkmans BA, Boers M. Ann Rheum Dis; 2009 Oct 15; 68(10):1652-3. PubMed ID: 19748920 [No Abstract] [Full Text] [Related]